Core Insights - Huajian Medical Holdings Limited and Renhe Pharmaceutical Co., Ltd. have reached a strategic cooperation agreement focused on OTC intellectual property, aiming to create a global benchmark for digital pharmaceutical assets [1][2] - This collaboration signifies Renhe Pharmaceutical's strategic shift from a traditional pharmaceutical company to a digital pharmaceutical ecosystem operator, highlighting its forward-looking approach in digital management of brand intellectual property [1][2] Industry Context - The global pharmaceutical industry is undergoing deep reforms in "R&D and operations," facing core issues such as "dormant intangible assets, low cross-border efficiency, and singular valuation logic" [2] - Huajian Medical, as an innovative service provider focused on digitalization in healthcare, possesses substantial industry resources and advanced digital asset solutions [2] - Renhe Pharmaceutical, a well-known player in China's OTC sector, has a robust portfolio including multiple national brands and a comprehensive production and distribution network, with 62 production lines and 832 drug approvals [2] Strategic Objectives - The partnership aims to systematically convert Renhe's brand intellectual property into digital assets, expanding brand value boundaries and providing new pathways for global operations [2] - The collaboration will focus on four key areas: digitalization of intellectual property, global market expansion, construction of an intelligent valuation system, and development of a digital ecosystem platform [2]